The round, which brought total funding to $26.84m, was led by strategic investor UCB, a global biopharmaceutical company, with participation from Adams Street Partners, Qiming US Ventures, CVS Health, The Westly Group, HealthTech Capital and 500 Startups.
The company intends to use the new funds to accelerate growth, including expansion of its existing social networks, as well as to launch additional social networks for people diagnosed with a chronic disease to connect with others living with similar challenges and to find relevant, objective information about managing their health.
Led by Eric Peacock, cofounder and CEO, MyHealthTeams creates social networks for people living with a chronic health condition. It currently operates 33 engaged communities focusing on the following conditions: Crohn’s and colitis, multiple sclerosis, lupus, fibromyalgia, pulmonary hypertension, spondylitis, eczema, myeloma, hyperhidrosis, rheumatoid arthritis, psoriasis, leukemia, lymphoma, irritable bowel syndrome, Parkinson’s, Alzheimer’s, epilepsy, hemophilia, hidradenitis suppurative, depression, heart disease, type 2 diabetes, osteoporosis, COPD, chronic pain, migraines, food allergies, obesity, HIV, PCOS, endometriosis, breast cancer and autism.
The company’s social networks are available in 13 countries.
MyHealthTeams partners with 9 of the top 10 global pharmaceutical companies and 19 other biopharma and healthcare companies.
FinSMEs
15/08/2019